Arcus Total Assets from 2010 to 2024

RCUS Stock

USD 15.79 1.23 8.45%

Arcus Biosciences Total Assets yearly trend continues to be comparatively stable with very little volatility. Total Assets will likely drop to about 767.6 M in 2024. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2016-12-31

Previous Quarter

1.2 B

Current Value

1.3 B

Quarterly Volatility

507.8 M

Covid

Check Arcus Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arcus Biosciences' main balance sheet or income statement drivers, such as Net Interest Income of 41 M, Interest Income of 43 M or Depreciation And Amortization of 6.1 M, as well as many indicators such as Price To Sales Ratio of 11.48, Dividend Yield of 0.0 or PTB Ratio of 3.39. Arcus financial statements analysis is a perfect complement when working with Arcus Biosciences Valuation or Volatility modules.

Check out the analysis of Arcus Biosciences Correlation against competitors.

For more information on how to buy Arcus Stock please use our How to Invest in Arcus Biosciences guide.

Latest Arcus Biosciences' Total Assets Growth Pattern

Below is the plot of the Total Assets of Arcus Biosciences over the last few years. Total assets refers to the total amount of Arcus Biosciences assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Arcus Biosciences books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Arcus Biosciences' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Arcus Biosciences' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 1.09 B

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Arcus Total Assets Regression Statistics

	Arithmetic Mean	467,213,786
	Geometric Mean	269,205,886
	Coefficient Of Variation	109.90
	Mean Deviation	431,427,048
	Median	190,486,000
	Standard Deviation	513,450,456
	Sample Variance	263631.4T
	Range	1.5B
	R-Value	0.78
	Mean Square Error	112728.6T
	R-Squared	0.60
	Significance	0.0007
	Slope	89,150,105
	Total Sum of Squares	3690839.2T

Arcus Total Assets History

	2024	767.6 M
	2023	1.1 B
	2022	1.3 B
	2021	1.6 B
	2020	772.3 M
	2019	203.1 M
	2018	274.9 M

Other Fundumenentals of Arcus Biosciences

Intangibles To Total Assets

Arcus Biosciences Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Capital Surpluse	Total Liab	Long Term Investments	Total Current Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Deferred Long Term Liab	Net Invested Capital	Net Working Capital	Short Term Debt	Capital Stock
Total Assets		0.99	0.93	-0.21	-0.73	0.85	0.67	0.86	0.9	0.99	0.95	0.93	0.59	0.66	0.98	-0.03	0.98	0.99	0.71	0.59
Total Stockholder Equity	0.99		0.92	-0.23	-0.67	0.81	0.7	0.83	0.88	0.95	0.91	0.91	0.5	0.57	0.96	0.03	1.0	0.99	0.78	0.5
Net Tangible Assets	0.93	0.92		-0.37	-0.88	0.83	0.53	0.86	0.99	0.92	0.85	0.9	0.72	0.77	0.94	0.09	0.92	0.93	0.69	0.71
Net Debt	-0.21	-0.23	-0.37		0.58	-0.58	0.39	-0.56	-0.45	-0.2	0.05	-0.48	-0.47	-0.45	-0.38	0.14	-0.21	-0.21	-0.03	-0.47
Retained Earnings	-0.73	-0.67	-0.88	0.58		-0.82	-0.13	-0.83	-0.93	-0.76	-0.63	-0.82	-0.92	-0.94	-0.79	-0.01	-0.66	-0.69	-0.32	-0.92
Accounts Payable	0.85	0.81	0.83	-0.58	-0.82		0.2	0.98	0.86	0.86	0.7	0.97	0.74	0.75	0.92	-0.14	0.81	0.83	0.38	0.74
Net Receivables	0.67	0.7	0.53	0.39	-0.13	0.2		0.21	0.42	0.62	0.76	0.35	-0.04	0.06	0.55	-0.02	0.71	0.7	0.87	-0.05
Short Term Investments	0.86	0.83	0.86	-0.56	-0.83	0.98	0.21		0.89	0.87	0.71	0.99	0.74	0.76	0.92	0.03	0.82	0.83	0.38	0.74
Capital Surpluse	0.9	0.88	0.99	-0.45	-0.93	0.86	0.42	0.89		0.9	0.8	0.91	0.78	0.83	0.93	0.09	0.88	0.89	0.6	0.78
Total Liab	0.99	0.95	0.92	-0.2	-0.76	0.86	0.62	0.87	0.9		0.96	0.92	0.66	0.72	0.97	-0.08	0.95	0.97	0.63	0.66
Long Term Investments	0.95	0.91	0.85	0.05	-0.63	0.7	0.76	0.71	0.8	0.96		0.8	0.56	0.63	0.89	-0.08	0.92	0.93	0.66	0.56
Total Current Assets	0.93	0.91	0.9	-0.48	-0.82	0.97	0.35	0.99	0.91	0.92	0.8		0.72	0.74	0.96	-0.01	0.89	0.91	0.49	0.72
Common Stock	0.59	0.5	0.72	-0.47	-0.92	0.74	-0.04	0.74	0.78	0.66	0.56	0.72		0.99	0.65	-0.12	0.51	0.55	0.03	1.0
Property Plant Equipment	0.66	0.57	0.77	-0.45	-0.94	0.75	0.06	0.76	0.83	0.72	0.63	0.74	0.99		0.7	-0.12	0.58	0.61	0.12	0.99
Current Deferred Revenue	0.98	0.96	0.94	-0.38	-0.79	0.92	0.55	0.92	0.93	0.97	0.89	0.96	0.65	0.7		-0.11	0.96	0.97	0.67	0.65
Deferred Long Term Liab	-0.03	0.03	0.09	0.14	-0.01	-0.14	-0.02	0.03	0.09	-0.08	-0.08	-0.01	-0.12	-0.12	-0.11		-0.03	-0.06	0.05	-0.13
Net Invested Capital	0.98	1.0	0.92	-0.21	-0.66	0.81	0.71	0.82	0.88	0.95	0.92	0.89	0.51	0.58	0.96	-0.03		1.0	0.79	0.51
Net Working Capital	0.99	0.99	0.93	-0.21	-0.69	0.83	0.7	0.83	0.89	0.97	0.93	0.91	0.55	0.61	0.97	-0.06	1.0		0.76	0.55
Short Term Debt	0.71	0.78	0.69	-0.03	-0.32	0.38	0.87	0.38	0.6	0.63	0.66	0.49	0.03	0.12	0.67	0.05	0.79	0.76		0.03
Capital Stock	0.59	0.5	0.71	-0.47	-0.92	0.74	-0.05	0.74	0.78	0.66	0.56	0.72	1.0	0.99	0.65	-0.13	0.51	0.55	0.03

Click cells to compare fundamentals

About Arcus Biosciences Financial Statements

Arcus Biosciences shareholders use historical fundamental indicators, such as Total Assets, to determine how well the company is positioned to perform in the future. Although Arcus Biosciences investors may analyze each financial statement separately, they are all interrelated. The changes in Arcus Biosciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on Arcus Biosciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

		Last Reported	Projected for Next Year
	Total Assets	1.1 B	767.6 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Arcus Stock Analysis

When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC